Abstract：【Objective】 To observe the efficacy of intravitreal injection of Ranibizumab in assisted Pars Plana Vitrectomy (PPV) for proliferative diabetic retinopathy (PDR) , and the effect on levels of vascular endothelial growth factor (VEGF), interleukin-6 (IL-6), IL-8 and monocyte chemokine protein-1 (MCP-1) .【Methods】 One hundred and forty-six patients with PDR (all monocular diseases) admitted to our hospital from June 2015 to June 2017 were selected and randomly divided into three groups: A, B and C. In the group A, 50 cases (50 eyes) were treated with PPV 4 days after Razumab injection; in the group B, 48 cases (48 eyes) were treated with PPV 10 days after Razumab injection; and in the group C, 48 cases (48 eyes) were treated with PPV operation only. The therapeutic effect was observed and the levels of vascular endothelial growth factor, interleukin-6, interleukin-8 and MCP-1 were compared before and after treatment. 【Results】 The operation time of the group A and group B was significantly shorter than that of the group C (P<0.05); the average bleeding times, electrocoagulation times and silicone oil filling rate were significantly less than those of the group C (P<0.05); but there was no significant difference in operation time, average bleeding times, electrocoagulation times and silicone oil filling rate between the group A and the group B (P>0.05). The incidence of vitreous hemorrhage and iatrogenic retinal hole in the group A and B was significantly lower than that in the group C (P<0.05); the proportion of patients with visual acuity of 0.3~0.5 and > 0.5 in the group A and B was significantly higher than that in the group C (P<0.05); the ratio of manual operation and anterior ocular index in the group A and B was significantly lower than that in the group C (P<0.05); the average intraocular pressure in the group A and B was significantly lower than that in the group C (P<0.05). Visual acuity was significantly higher than that of the group C (P<0.05), but there was no significant difference between the group A and the group B (P>0.05). On the 7th day after treatment, the levels of VEGF and IL-18 in aqueous humor of the group A and the group B were significantly lower than those of the group C, and the levels of IL-6 and MCP-1 were significantly higher than those of the group C (P<0.05), but there was no significant difference between the group A and the group B (P>0.05).【Conclusion】 The intravitreal injection of Ranibizumab-assisted PPV is effective in the treatment of proliferative diabetic retinopathy. It can effectively improve the visual acuity of patients, and has a high application value. It is an ideal time for injection 4 days before surgery.
[1] 张鹏,尚庆丽,马景学,等.增生型糖尿病视网膜病变患者玻璃体切割手术后新生血管性青光眼危险因素分析[J].中华眼底病杂志, 2017,33(3):271-274. [2] Sassa Y, Yoshida S, Ishikawa K, et al. The kinetics of VEGF and MCP-1 in the second vitrectomy cases with proliferative diabetic retinopathy[J]. Eye, 2016, 30(5):746-753. [3] 楚艳华,刘玉燕,王莹,等.增生型糖尿病视网膜病变患眼玻璃体切割手术后玻璃体再积血原因及预后观察分析[J].中华眼底病杂志,2017,33(4):391-395. [4] Chiefari E, Ventura V, Capula C, et al. A polymorphism of HMGA1 protects against proliferative diabetic retinopathy by impairing HMGA1-induced VEGFA expression[J]. Sci Rep, 2016,38(6):39429. [5] 陈静,赖铭莹,罗恒等.抗VEGF药物联合激光光凝治疗糖尿病性黄斑水肿观察研究[J].中国实用眼科杂志,2014,32(6):693-697. [6] 付浴东,王萍,江莉等.玻璃体腔注射雷珠单抗、全视网膜激光光凝对增生型糖尿病视网膜病变患眼玻璃体切割手术及治疗效果的影响[J].中华眼底病杂志,2015,31(2):143-146. [7] 第三届全国眼科学术会议.糖尿病性视网膜病变分期标准[J].中华眼科杂志,1985,21(2):113. [8] 周爱意, 李婷, 赵琳,等.玻璃体切割联合白内障超声乳化术治疗增生性糖尿病视网膜病变临床研究[J].中国实用眼科杂志,2016,34(1):58-61. [9] Gonzalezsalinas R, Garciagutierrez M C, Garciaaguirre G, et al. Evaluation of VEGF gene polymorphisms and proliferative diabetic retinopathy in Mexican population[J]. Int J Ophthalmol, 2017, 10(1):135. [10] 高静,刘晓,王敏哲,等.VEGF、SDF-1在糖尿病视网膜血管病变发生、发展中的作用及机制[J].新疆医科大学学报,2016,39(10):1286-1290. [11] 单俊杰,袁志兰,曹国平,等.玻璃体腔注射阿瓦斯汀、雷珠单克隆抗体后糖尿病视网膜患者血清中 VEGF含量的变化研究[J].临床眼科杂志,2015,23(4):330-332. [12] 吕勇,范琼艳,杨琳,等.老年白内障手术联合玻璃体腔注射雷珠单抗对糖尿病性黄斑水肿影响[J].中国实用眼科杂志,2014,32(5):560-563. [13] 王伟超,张洁,王虹,等.社区中老年糖尿病视网膜病变患者泪液IL-6与血液HbA1c关系分析[J].实用医学杂志,2015,31(18):3084-3087. [14] 丁国龙,谢安明,雷剑琴,等.增生型糖尿病视网膜病变患者玻璃体内注射贝伐单抗后房水中细胞因子的变化及其相关性分析[J].眼科新进展,2017,37(4):358-361.
2019, Vol. 36 
